ClinicalTrials.gg
Status unknownNCT05198817Updated Jun 28, 2022

A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients

A Phase 1 interventional study of SHR-2002 injection、Camrelizumab for Injection, SHR-1316 injection, SHR-1701 injection in Advanced Malignant Tumors, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Status unknown at 5 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-06-28.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2022), so the status shown — last known as Enrolling by invitation — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
240
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of SHR-2002 injection monotherapy and in combination with other anti-cancer therapy for advanced malignant tumors of patients. To explore the reasonable dosage of SHR-2002 injection monotherapy and dosage regimen of combination therapy for advanced malignant tumors of patients.

02

Conditions studied

  • Advanced Malignant Tumors
03

In context

Lead sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd. is the lead sponsor of 104 studies on the registry; 73 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to understand and voluntarily agrees to participate by giving written for the study;
  2. Male or female aged ≥18 years and ≤70 years at the time of signing the ICF;
  3. Histopathologically or documented advanced or ;
  4. An (ECOG) performance status (PS) score of 0 or 1;
  5. ≥12 weeks;
  6. Adequate organ functions as defined;
  7. Female and male patients of must agree to use highly effective during the study treatment period and within 6 months after the last drug administration; Female of must have a negative serum human chorionic gonadotropin (HCG) test within 7 days before the first dose of the investigational drugs and must not be breastfeeding.

Exclusion criteria

Exclusion Criteria:

  1. Patients with known active central nervous system (CNS) and/or carcinomatous meningitis;
  2. Patients with active (without medical control or with clinical symptoms), cancerous meningitis, spinal cord compression, or patients with a history of primary tumors of the central nervous system ;
  3. Patients with tumor-related pain that cannot be controlled as determined by the investigator;
  4. Uncontrollable third-space effusion, such as pleural effusion, pericardial effusion or peritoneal effusion;
  5. Systemic anti-tumor therapy within 28 days prior to the first dose of the study treatment;
  6. Surgical procedures requiring general anesthesia within 28 days prior to the first dose of the study treatment;
  7. Patients who have received >30 Gy of radical radiotherapy within 28 days before the first dose of study treatment;
  8. Unresolved Grade >1 toxicity attributed to any prior anti-tumor therapy;
  9. Use of within 28 days before the first dose of the study treatment;
  10. Patients who have received any systemic within 14 days prior to the first dose of study treatment;
  11. Patients with interstitial pneumonitis or interstitial lung disease; past history of interstitial pneumonitis or interstitial lung disease requiring hormone therapy;
  12. History of diseases;
  13. History of bleeding symptom or bleeding tendency within 3 months before the first dose of study treatment;
  14. History of clinically significant cardiovascular or cerebrovascular diseases within 6 months prior to the first dose of study treatment;
  15. Evidence or history of arterial/venous thrombosis within 3 months before the first dose;
  16. Prior (other than current malignant tumor) within 5 ears before the first dose of study treatment;
  17. Known history of serious allergic reactions to the product or its main ingredients;
  18. History of immunodeficiency;
  19. Presence of active or active ;
  20. Severe infections within 4 weeks prior to the first study treatment;
  21. Evidence or history of active pulmonary tuberculosis within 1 year before study entry;
  22. any other conditions that are not suitable for participation in the study in the investigator's opinion.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Single Group

    Drug: SHR-2002 injection、Camrelizumab for Injection, SHR-1316 injection, SHR-1701 injection

Interventions

  • DrugSHR-2002 injection、Camrelizumab for Injection, SHR-1316 injection, SHR-1701 injection

    Drug pages: Adebrelimab · SHR-1701

    Firstly Dose Escalation and Dose Expansion of SHR-2002 injection monotherapy should be conducted. After RP2D and MTD of the SHR-2002 injection monotherapy were confirmed, Dose Escalation, Dose Expansion and Efficacy Expansion of SHR-2002 injection in combination with other anti-cancer treatment would be completed, including Camrelizumab for Injection, or SHR-1316 injection, or SHR-1701 injection.

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose

    The Maximum tolerated dose of SHR-2002 injection monotherapy or in combination with Camrelizumab for Injection, or SHR-1316 injection, or SHR-1701 injection

    Time frame: first dose of study medication up to 21 days

  2. Recommended phase II dose

    The Recommended phase II dose of SHR-2002 injection monotherapy or in combination with Camrelizumab for Injection, or SHR-1316 injection, or SHR-1701 injection

    Time frame: first dose of study medication up to 21 days

  3. Incidence and severity of adverse events (AEs)/serious adverse events (SAEs)

    Incidence and severity of adverse events (AEs)/serious adverse events (SAEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.0

    Time frame: from signature completion of ICF to 90 days after the last dose or to the beginning of the new anti-cancer therapy, whichever came first, assessed up to 24 weeks

Secondary outcomes

  1. Tmax

    PK parameters of single dose of SHR-2002 injection monotherapy

    Time frame: 0.5 hour before first dose to the 336 hours after first dose

  2. Cmax

    PK parameters of single dose of SHR-2002 injection monotherapy

    Time frame: 0.5 hour before first dose to the 336 hours after first dose

  3. AUC0-t

    PK parameters of single dose of SHR-2002 injection monotherapy

    Time frame: 0.5 hour before first dose to the 336 hours after first dose

  4. AUC0-∞

    PK parameters of single dose of SHR-2002 injection monotherapy

    Time frame: 0.5 hour before first dose to the 336 hours after first dose

  5. t1/2

    PK parameters of single dose of SHR-2002 injection monotherapy

    Time frame: 0.5 hour before first dose to the 336 hours after first dose

  6. CL

    PK parameters of single dose of SHR-2002 injection monotherapy

    Time frame: 0.5 hour before first dose to the 336 hours after first dose

  7. Vss

    PK parameters of single dose of SHR-2002 injection monotherapy

    Time frame: 0.5 hour before first dose to the 336 hours after first dose

  8. Cmax, ss

    PK parameters of multiple doses of SHR-2002 monotherapy

    Time frame: 0.5 hour before second dose to the 30 days after last dose

  9. Ctrough, ss

    PK parameters of multiple doses of SHR-2002 monotherapy

    Time frame: 0.5 hour before second dose to the 30 days after last dose

  10. Rac

    PK parameters of multiple doses of SHR-2002 monotherapy

    Time frame: 0.5 hour before second dose to the 30 days after last dose

  11. RO

    Receptor occupancy, PD indicators of SHR-2002 injection monotherapy

    Time frame: 0.5 hour before second dose to the 30 days after last dose

  12. Cytokine concentration

    PD indicators of SHR-2002 injection monotherapy

    Time frame: 0.5 hour before second dose to the 30 days after last dose

  13. Ctrough, ss

    PK parameters of SHR -2002, Camrelizumab for Injection, SHR-1316 injection and SHR-1701 injection during combination therapy period

    Time frame: 0.5 hour before second dose to the 90 days after last dose

  14. Rac

    PK parameters of SHR -2002, Camrelizumab for Injection, SHR-1316 injection and SHR-1701 injection during combination therapy period

    Time frame: 0.5 hour before second dose to the 90 days after last dose

  15. ADA

    Anti-drug antibody, Immunogenicity of SHR-2002 in monotherapy and combination therapy, Camrelizumab for Injection, SHR-1316 injection and SHR-1701 injection

    Time frame: 0.5 hour before second dose to the 90 days after last dose

  16. NAb

    Immunogenicity of Camrelizumab for Injection, SHR-1316 injection and SHR-1701 injection

    Time frame: 0.5 hour before second dose to the 90 days after last dose

  17. ORR

    Objective Response Rate, Efficacy endpoints of SHR-2002 injection monotherapy or in combination with Camrelizumab for Injection, or SHR-1316 injection, or SHR-1701 injection in treatment of patients with Advanced Malignant Tumors

    Time frame: from the date of the first dose to the date of disease progression evaluated based on RECIST v1.1 criteria, death, lost to follow-up, voluntary withdrawal, or initiation of other anti-tumor treatment, whichever occurs first, assessed up to 6 months]

  18. DoR

    Duration of response, Efficacy endpoints of SHR-2002 injection monotherapy or in combination with Camrelizumab for Injection, or SHR-1316 injection, or SHR-1701 injection in treatment of patients with Advanced Malignant Tumors

    Time frame: from the date of the firstly documented tumor response to the date of the firstly documented disease progression or the date of death for any reason, assessed up to 6 months

  19. DCR

    Disease control rate, Efficacy endpoints of SHR-2002 injection monotherapy or in combination with Camrelizumab for Injection, or SHR-1316 injection, or SHR-1701 injection in treatment of patients with Advanced Malignant Tumors

    Time frame: from the date of the first dose to the date of the firstly documented disease progression (evaluated based on RECIST v1.1 criteria) or the date of death for any reason, assessed up to 6 months

  20. PFS

    Progression-free survival, Efficacy endpoints of SHR-2002 injection monotherapy or in combination with Camrelizumab for Injection, or SHR-1316 injection, or SHR-1701 injection in treatment of patients with Advanced Malignant Tumors

    Time frame: from the date of the first dose to the date of the firstly documented disease progression (evaluated based on RECIST v1.1 criteria) or the date of death for any reason, assessed up to 6 months

  21. OS

    Overall survival, Efficacy endpoints of SHR-2002 injection monotherapy or in combination with Camrelizumab for Injection, or SHR-1316 injection, or SHR-1701 injection in treatment of patients with Advanced Malignant Tumors

    Time frame: from the date of the first dose to the date of death for any reason,assessed up to 100 months

07

Study locations

5 sites
  • Henan Science and Technology University First Affiliated Hospital
    Luoyang, Henan 471003, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410006, China
  • Linyi Cancer Hospital
    Linyi, Shandong 276002, China
  • Shanghai Pulmonary Hospital
    Shanghai, Shanghai 200433, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 410013, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2022 (actual). Primary completion is estimated for Jan 2023, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2022
First posted
Jan 20, 2022
StartActual
Feb 22, 2022
Primary completionEst.
Jan 31, 2023
CompletionEst.
Jun 30, 2023
Last update
Jun 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05198817
Responsible party
Sponsor
First posted
Jan 20, 2022
Start date
Feb 22, 2022
Primary completion
Jan 31, 2023 (estimated)
Completion
Jun 30, 2023 (estimated)
Last update
Jun 28, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adebrelimab · SHR-1701

Start the discussion